(Total Views: 335)
Posted On: 12/06/2020 1:40:04 PM
Post# of 721
The perfect storm to unfold?
Following the ups and downs with LXRP the last 3-4 months, I think we are in for a period of good news, that will follow up on all progress going on. Lexaria receives ethics board ok to launch human study with DehydraTech for delivering antivirals; with all set up, it will start in the first month of 2021. (2 months ago, video) https://youtu.be/7kFI3mX8quk
One of the benefits LXRP has is it`s not depending on one customer or even one sector; though focus mainly on the PHARMA for now, I consider the right decision. With Pharma background from most of the team, it comes as the most natural step to give all effort now to establish ONE drug (multiple options) with DehydraTech formula.
This One, especially if it`s a "essential drug", will be o door opener for Lexaria. Though nothing is certain, I consider Chris with team has made a good work to position the company very well going in to a new year.
Following the ups and downs with LXRP the last 3-4 months, I think we are in for a period of good news, that will follow up on all progress going on. Lexaria receives ethics board ok to launch human study with DehydraTech for delivering antivirals; with all set up, it will start in the first month of 2021. (2 months ago, video) https://youtu.be/7kFI3mX8quk
One of the benefits LXRP has is it`s not depending on one customer or even one sector; though focus mainly on the PHARMA for now, I consider the right decision. With Pharma background from most of the team, it comes as the most natural step to give all effort now to establish ONE drug (multiple options) with DehydraTech formula.
This One, especially if it`s a "essential drug", will be o door opener for Lexaria. Though nothing is certain, I consider Chris with team has made a good work to position the company very well going in to a new year.
(1)
(0)
Robert
